Pulmatrix Inc
(NASDAQ : PULM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.04%79.980.9%$596.63m
CELGCelgene Corporation
1.72%139.061.1%$557.44m
AMGNAmgen Inc.
1.00%183.711.1%$431.76m
BIIBBiogen Inc.
3.45%347.251.2%$381.15m
REGNRegeneron Pharmaceuticals, Inc.
-0.02%445.612.7%$321.83m
ALNYAlnylam Pharmaceuticals, Inc
-1.48%120.0810.7%$266.06m
VRTXVertex Pharmaceuticals Incorporated
0.15%154.931.9%$226.20m
INCYIncyte Corporation
-0.57%115.942.5%$208.52m
ALXNAlexion Pharmaceuticals, Inc.
2.63%144.541.9%$182.97m
ILMNIllumina, Inc.
-0.46%205.283.5%$140.43m
EXELExelixis, Inc.
0.38%29.136.5%$134.73m
CLVSClovis Oncology, Inc.
-3.59%81.5416.5%$126.62m
BLUEBluebird Bio, Inc.
-2.86%139.2017.3%$118.51m
SRPTSarepta Therapeutics, Inc.
1.05%51.2616.9%$111.85m
BMRNBioMarin Pharmaceutical Inc.
0.24%94.894.4%$105.02m

Company Profile

Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. It designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Edwards, Mark Gabrielson, Alexander Klibanov, and Robert Langer in 2013 and is headquartered in Lexington, MA.